Neoadjuvant pembrolizumab with low-dose chemotherapy demonstrated promising efficacy and acceptable safety in advanced EC, with favorable outcomes in high-grade malignancies regardless of molecular subtype. These findings warrant further investigation in selected patients.
Chao et al. (Sun,) studied this question.